<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080205</url>
  </required_header>
  <id_info>
    <org_study_id>BariBrain-PET</org_study_id>
    <secondary_id>T153/2018</secondary_id>
    <nct_id>NCT05080205</nct_id>
  </id_info>
  <brief_title>Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, Insulin Resistance and Central Reward System</brief_title>
  <acronym>BariBrainPET</acronym>
  <official_title>Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, Insulin Resistance and Activation of Central Reward System Studied Using PET- and MRI-imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Morbid obesity is associated with decreased brain µ-opioid receptor availability,&#xD;
      possibly resulting in higher food intake needed to gain pleasure from eating. This decrease&#xD;
      seems to normalize already 6 months after bariatric surgery, but the longer-term effects have&#xD;
      not been studied. Obesity and insulin resistance result in significantly increased brain&#xD;
      insulin-stimulated glucose uptake, whereas in every other tissue glucose uptake is lower. One&#xD;
      possible explanation to this could be central inflammation and activation of brain glial&#xD;
      cells, which has been shown to occur in animal models of obesity. Obesity has also been shown&#xD;
      to associate with increased risk of Alzheimer's disease and cognitive decline in several&#xD;
      studies.&#xD;
&#xD;
      Aims: The first objective of this study is to both study the effects of bariatric surgery as&#xD;
      well as compare the effects of gastric bypass and sleeve gastrectomy on food-associated&#xD;
      pleasure, extending the follow-up period to 2 years postoperatively. The second aim is to&#xD;
      investigate the effect of morbid obesity and weight loss on brain inflammation and gliosis&#xD;
      and its association with increased brain insulin-stimulated glucose uptake. Furthermore,&#xD;
      association of obesity, insulin resistance, central inflammation and neurocognitive&#xD;
      dysfunction are evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: A total of 60 morbidly obese subjects, 30 assigned for Roux-en-Y gastric bypass and&#xD;
      30 for sleeve gastrectomy according to routine treatment protocols will be recruited for this&#xD;
      study. A control group of 30 healthy subjects will also be recruited. We will perform 1)&#xD;
      structural MRI and MRS, 2) functional MRI during tasting and visual food cues, 3) PET imaging&#xD;
      of µ-opioid receptor availability using [11C]-carfentanil, 4) PET imaging of cerebral&#xD;
      inflammation and astrocyte activation using [11C]-PK11195, 5) measurement of whole-body and&#xD;
      tissue insulin sensitivity by combining hyperinsulinemic, euglycemic clamp with&#xD;
      [18F]-FDG-PET, 6) neuropsychological testing. The control group will only be studied once,&#xD;
      whereas study procedures will be repeated for the morbidly obese before very-low calorie diet&#xD;
      and 6, 12 and 24 months postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 11, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">October 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>60 subjects undergoing bariatric surgery (either Roux-en-Y gastric bypass or Sleeve gastrectomy) and 30 healthy controls</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in central inflammation</measure>
    <time_frame>Controls: 0 months; Morbidly obese: preoperatively, 6 months postoperatively</time_frame>
    <description>Assessment of brain glial cell activation using [11C]-PK11195 tracer and positron emission tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in central reward system using fMRI imaging</measure>
    <time_frame>Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months, 24 months postoperatively</time_frame>
    <description>Assessment of brain reward system activation after visual/taste cues using functional MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain μ-opioid receptor availability using PET imaging</measure>
    <time_frame>Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months postoperatively</time_frame>
    <description>Assessment of brain μ-opioid receptor availability using [11C]-carfentanil tracer and positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognitive function studied with testing</measure>
    <time_frame>Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months, 24 months postoperatively</time_frame>
    <description>Neuropsychological testing focusing on memory, decision-making and inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in whole-body insulin sensitivity usign FDG-PET imaging</measure>
    <time_frame>Controls: 0 months; Morbidly obese: preoperatively, 6 months postoperatively</time_frame>
    <description>Assessment of whole-body insulin sensitivity using hyperinsulinemic, euglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tissue-specific insulin sensitivity using FDG-PET imaging</measure>
    <time_frame>Controls: 0 months; Morbidly obese: preoperatively</time_frame>
    <description>Assessment of insulin-stimulated glucose uptake in the brain, liver, skeletal muscle and adipose tissue by performing positron emission tomography with [18F]-fluorodeoxyglucose tracer during hyperinsulinemic, euglycemic clamp</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Morbidly obese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-obese controls are only studied at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process</description>
    <arm_group_label>Morbidly obese subjects</arm_group_label>
    <other_name>Roux-en-Y gastric bypass</other_name>
    <other_name>Sleeve gastrectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Morbidly obese group&#xD;
&#xD;
          1. BMI 35.0-45.0 kg/m2, or BMI 32.0-45.0 kg/m2 and diagnosed diabetes&#xD;
&#xD;
          2. Age 18-60 years&#xD;
&#xD;
          3. Eligible to bariatric surgery evaluated according to normal treatment paradigm&#xD;
&#xD;
        Non-obese controls&#xD;
&#xD;
          1. BMI 18-27 kg/m2&#xD;
&#xD;
          2. Age 18-60 years&#xD;
&#xD;
          3. Fasting plasma glucose ≤6.1 mmol/L&#xD;
&#xD;
          4. Normal values in 2-hour oral glucose tolerance test&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Morbidly obese group&#xD;
&#xD;
          1. Metal objects in the body (including pacemakers, metallic artificial valve prostheses,&#xD;
             inner ear implants, surgical clipses, braces, foreign fragments)&#xD;
&#xD;
          2. Previous participation in PET studies&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Poor compliance, alcohol or drug abuse&#xD;
&#xD;
          5. Weight over 150 kg or waist circumference over 150 cm&#xD;
&#xD;
          6. Diabetes with fasting glucose levels ≥7.0 mmol/L, or treatment with insulin&#xD;
&#xD;
          7. Any chronic disease, medication or condition that could create a hazard to subject&#xD;
             safety, endanger study procedures or interfere with the interpretation of results.&#xD;
&#xD;
        Non-obese controls&#xD;
&#xD;
          1. Metal objects in the body (including pacemakers, metallic artificial valve prostheses,&#xD;
             inner ear implants, surgical clipses, braces, foreign fragments)&#xD;
&#xD;
          2. Previous participation in PET studies&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Poor compliance, alcohol or drug abuse&#xD;
&#xD;
          5. Smoking&#xD;
&#xD;
          6. History of eating disorders, drastic weight-gain or weight-loss&#xD;
&#xD;
          7. History of psychiatric disorders&#xD;
&#xD;
          8. Any chronic disease, medication or condition that could create a hazard to subject&#xD;
             safety, endanger study procedures or interfere with the interpretation of results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirjo Nuutila, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Pirjo Nuutila</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>central nervous system inflammation</keyword>
  <keyword>bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Under preparation.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

